Trial Profile
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus and Pre-diabetes and Heart Failure (SUGAR-DM-HF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUGAR-DM-HF
- 28 Aug 2023 Primary endpoint (Left Ventricular End Systolic Volume Index (LVESVI)) has not been met according to Results presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
- 28 Aug 2023 Results assessing the effect of empagliflozin on CMR-PCWP and the relationship between CMR-PWCP and the remodelling effect of empagliflozin presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 10 Aug 2020 Status changed from active, no longer recruiting to completed.